US Patent

US10570139 — Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators

Method of Use · Assigned to BeiGene Switzerland GmbH · Expires 2034-04-22 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects fused heterocyclic compounds that can be used to inhibit Bruton's tyrosine kinase and treat disorders mediated thereby.

USPTO Abstract

The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

Drugs covered by this patent

Brukinsa (ZANUBRUTINIB) · BeiGene

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1745`	—	Brukinsa
`U-1745`	—	Brukinsa

Patent Metadata

Patent number: US10570139
Jurisdiction: US
Classification: Method of Use
Expires: 2034-04-22
Drug substance claim: No
Drug product claim: No
Assignee: BeiGene Switzerland GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.